PEG-asparaginase
Phase 3Protein / enzyme
AmgenPEG-asparaginase is one of 105 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Phase 3.
6
Indications
23
Total Trials
4
Active Trials
104
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Medrol
PfizerPhase 3
Arranon
NovartisPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Zinecard
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia11 trials
Show 8 more trials
T-cell acute lymphoblastic leukemia2 trials
Lymphoblastic Lymphoma2 trials
Relapsed/Refractory1 trial
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
Completed·—·Phase 1·NCT03349281·6 enrolled
6 more indications
Adult Acute Lymphoblastic Leukemia1 trial
Adult ALL1 trial
ALL Adult Consortium Trial: Adult ALL Trial
Completed·—·Phase 2·NCT00476190·112 enrolled
Treatment1 trial
Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses
Unknown status·NNordic Society for Pediatric Hematology and Oncology·Phase 4·NCT00192673·85 enrolled
Induction Chemotherapy1 trial
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
Completed·—·Phase 1·NCT01523977·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PEG-asparaginase. EMBL-EBI & Wellcome Sanger Institute.
- [4]